AnaptysBio Inc (ANAB) concluded trading on Wednesday at a closing price of $16.15, with 13.79 million shares of worth about $222.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.15% during that period and on February 12, 2025 the price saw a gain of about 30.51%. Currently the company’s common shares owned by public are about 30.43M shares, out of which, 25.91M shares are available for trading.
Stock saw a price change of 0.56% in past 5 days and over the past one month there was a price change of 10.47%. Year-to-date (YTD), ANAB shares are showing a performance of 21.98% which decreased to -29.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $12.21 but also hit the highest price of $41.31 during that period. The average intraday trading volume for AnaptysBio Inc shares is 672.08K. The stock is currently trading 0.13% above its 20-day simple moving average (SMA20), while that difference is down -3.10% for SMA50 and it goes to -38.41% lower than SMA200.
AnaptysBio Inc (NASDAQ: ANAB) currently have 30.43M outstanding shares and institutions hold larger chunk of about 105.31% of that.
The stock has a current market capitalization of $491.42M and its 3Y-monthly beta is at 0.03. It has posted earnings per share of -$6.07 in the same period. It has Quick Ratio of 10.23 while making debt-to-equity ratio of 4.35. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ANAB, volatility over the week remained 15.14% while standing at 9.25% over the month.
Stock’s fiscal year EPS is expected to drop by -0.07% while it is estimated to increase by 13.30% in next year. EPS is likely to grow at an annualized rate of 4.69% for next 5-years, compared to annual growth of -19.45% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on February 04, 2025 offering an Outperform rating for the stock and assigned a target price of $25 to it. Coverage by H.C. Wainwright stated AnaptysBio Inc (ANAB) stock as a Neutral in their note to investors on December 11, 2024, suggesting a price target of $19 for the stock. On December 02, 2024, BTIG Research Downgrade their recommendations, while on July 22, 2024, H.C. Wainwright Initiated their ratings for the stock with a price target of $55. Stock get an Overweight rating from JP Morgan on July 19, 2024.
